PHARMING GROUP NV - ADR (PHAR) Stock Fundamental Analysis
USA - NASDAQ:PHAR - US71716E1055 - ADR
13.79 USD
-1.01 (-6.82%)
14 USD
+0.21 (+1.52%)
We assign a fundamental rating of 5 out of 10 to PHAR. PHAR was compared to 536 industry peers in the Biotechnology industry. PHAR has an average financial health and profitability rating. PHAR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PHAR has reported negative net income.
PHAR had a positive operating cash flow in the past year.
In multiple years PHAR reported negative net income over the last 5 years.
In multiple years PHAR reported negative operating cash flow during the last 5 years.
1.2 Ratios
PHAR has a better Return On Assets (-1.84%) than 88.62% of its industry peers.
With an excellent Return On Equity value of -3.42%, PHAR belongs to the best of the industry, outperforming 90.67% of the companies in the same industry.
PHAR has a Return On Invested Capital of 5.41%. This is amongst the best in the industry. PHAR outperforms 92.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.84% | ||
| ROE | -3.42% | ||
| ROIC | 5.41% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHAR has a Operating Margin of 7.21%. This is amongst the best in the industry. PHAR outperforms 91.04% of its industry peers.
PHAR has a better Gross Margin (89.31%) than 91.04% of its industry peers.
PHAR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.21% | ||
| PM (TTM) | N/A | ||
| GM | 89.31% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
PHAR has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
PHAR has more shares outstanding than it did 1 year ago.
PHAR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PHAR has an improved debt to assets ratio.
2.2 Solvency
PHAR has an Altman-Z score of 3.29. This indicates that PHAR is financially healthy and has little risk of bankruptcy at the moment.
PHAR has a better Altman-Z score (3.29) than 71.83% of its industry peers.
The Debt to FCF ratio of PHAR is 4.26, which is a neutral value as it means it would take PHAR, 4.26 years of fcf income to pay off all of its debts.
PHAR has a Debt to FCF ratio of 4.26. This is amongst the best in the industry. PHAR outperforms 92.91% of its industry peers.
A Debt/Equity ratio of 0.50 indicates that PHAR is not too dependend on debt financing.
PHAR has a Debt to Equity ratio of 0.50. This is in the lower half of the industry: PHAR underperforms 72.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.26 | ||
| Altman-Z | 3.29 |
ROIC/WACC0.78
WACC6.94%
2.3 Liquidity
A Current Ratio of 2.79 indicates that PHAR has no problem at all paying its short term obligations.
The Current ratio of PHAR (2.79) is worse than 66.60% of its industry peers.
A Quick Ratio of 2.07 indicates that PHAR has no problem at all paying its short term obligations.
PHAR's Quick ratio of 2.07 is on the low side compared to the rest of the industry. PHAR is outperformed by 72.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.00% over the past year.
The Revenue has grown by 22.44% in the past year. This is a very strong growth!
Measured over the past years, PHAR shows a quite strong growth in Revenue. The Revenue has been growing by 10.64% on average per year.
EPS 1Y (TTM)35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
Revenue 1Y (TTM)22.44%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%25.79%
3.2 Future
PHAR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 61.94% yearly.
PHAR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.43% yearly.
EPS Next Y308.75%
EPS Next 2Y134.62%
EPS Next 3Y79.43%
EPS Next 5Y61.94%
Revenue Next Year18.48%
Revenue Next 2Y13.36%
Revenue Next 3Y11.65%
Revenue Next 5Y9.43%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHAR. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 21.82 indicates a rather expensive valuation of PHAR.
Based on the Price/Forward Earnings ratio, PHAR is valued cheaply inside the industry as 91.79% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.05, PHAR is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.82 |
4.2 Price Multiples
PHAR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PHAR is cheaper than 92.91% of the companies in the same industry.
93.28% of the companies in the same industry are more expensive than PHAR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.36 | ||
| EV/EBITDA | 22.69 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PHAR's earnings are expected to grow with 79.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y134.62%
EPS Next 3Y79.43%
5. Dividend
5.1 Amount
PHAR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.79
-1.01 (-6.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners14.71%
Inst Owner Change13.98%
Ins Owners1.38%
Ins Owner ChangeN/A
Market Cap944.82M
Analysts88.57
Price Target21.07 (52.79%)
Short Float %0.01%
Short Ratio0.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.45%
Min EPS beat(2)-42.39%
Max EPS beat(2)123.3%
EPS beat(4)2
Avg EPS beat(4)19%
Min EPS beat(4)-42.39%
Max EPS beat(4)123.3%
EPS beat(8)3
Avg EPS beat(8)-53.99%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)11.02%
Min Revenue beat(2)8.68%
Max Revenue beat(2)13.37%
Revenue beat(4)3
Avg Revenue beat(4)6.98%
Min Revenue beat(4)-5.54%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)2.17%
Revenue beat(12)6
Avg Revenue beat(12)-0.82%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.31%
PT rev (3m)23.01%
EPS NQ rev (1m)96.67%
EPS NQ rev (3m)89.76%
EPS NY rev (1m)5880.33%
EPS NY rev (3m)92.99%
Revenue NQ rev (1m)8.79%
Revenue NQ rev (3m)11.23%
Revenue NY rev (1m)0.7%
Revenue NY rev (3m)3.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.82 | ||
| P/S | 2.78 | ||
| P/FCF | 31.36 | ||
| P/OCF | 30.43 | ||
| P/B | 3.94 | ||
| P/tB | 9.12 | ||
| EV/EBITDA | 22.69 |
EPS(TTM)-0.13
EYN/A
EPS(NY)0.63
Fwd EY4.58%
FCF(TTM)0.44
FCFY3.19%
OCF(TTM)0.45
OCFY3.29%
SpS4.96
BVpS3.5
TBVpS1.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.84% | ||
| ROE | -3.42% | ||
| ROCE | 6.84% | ||
| ROIC | 5.41% | ||
| ROICexc | 8.34% | ||
| ROICexgc | 20.09% | ||
| OM | 7.21% | ||
| PM (TTM) | N/A | ||
| GM | 89.31% | ||
| FCFM | 8.87% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score6
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.26 | ||
| Debt/EBITDA | 2.95 | ||
| Cap/Depr | 5.84% | ||
| Cap/Sales | 0.27% | ||
| Interest Coverage | 3.72 | ||
| Cash Conversion | 77.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.07 | ||
| Altman-Z | 3.29 |
F-Score6
WACC6.94%
ROIC/WACC0.78
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
EPS Next Y308.75%
EPS Next 2Y134.62%
EPS Next 3Y79.43%
EPS Next 5Y61.94%
Revenue 1Y (TTM)22.44%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%25.79%
Revenue Next Year18.48%
Revenue Next 2Y13.36%
Revenue Next 3Y11.65%
Revenue Next 5Y9.43%
EBIT growth 1Y248.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year279.47%
EBIT Next 3Y79.88%
EBIT Next 5Y88.46%
FCF growth 1Y288.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y313.32%
OCF growth 3YN/A
OCF growth 5YN/A